Rivian Stock Rises After Strong Quarter

Rivian stock climbed after a stronger quarter and a Baird upgrade, while management's reaffirmed EBITDA and capex guidance tempered trading flows.

December 18, 2025·2 min read
View all news articles
Flat vector of an electric pickup under a split spotlight representing Rivian stock optimism tempered by reaffirmed guidance.

KEY TAKEAWAYS

  • Rivian reported $1.6 billion revenue, beating consensus and narrowing EPS loss.
  • Management reaffirmed 2025 adjusted EBITDA loss guidance of $2.0-$2.3 billion and $1.8-$1.9 billion capex.
  • Robert W. Baird raised its price target to $25 and upgraded Rivian, triggering a 15% stock move.

HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX

Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.

Or subscribe with

Rivian stock rose sharply after the company reported a stronger-than-expected quarter and an analyst upgrade, boosting optimism about the R2 platform while management reaffirmed its 2025 loss and capital-expenditure guidance.

Quarterly Results and Market Reaction

Rivian Automotive Inc. (RIVN) reported revenue of $1.56 billion for the quarter ended in late 2025, exceeding the $1.27 billion consensus and marking a 78.0% increase year over year. The company posted an EPS loss of $0.65 a share, narrower than the $0.71 expected.

Following the results, Robert W. Baird upgraded Rivian from Neutral to Outperform and raised its price target from $14 to $25, an increase of nearly 80%. The stock jumped about 15% on heavy volume after the upgrade, closing at $17.63 on December 17, 2025, with over 32 million shares traded. Despite the rally, analyst sentiment remains mixed, with 8 Buys, 13 Holds, and 6 Sells, and a consensus price target of $15.34.

Guidance and Capital Plan

On its earnings call, Rivian reaffirmed full-year 2025 adjusted EBITDA loss guidance of $2.0 billion to $2.25 billion and capital expenditures of $1.8 billion to $1.9 billion. Management said this outlook reflects continued investment to scale production, improve manufacturing efficiency, and fund technology development, including software and autonomy.

Asset sales and securities transactions contributed to near-term liquidity, generating $857 million in the fourth quarter of 2024 and $683 million in the third quarter of 2025.

Analysts view the R2 platform as Rivian’s key to expanding into the mass market and improving scale economics. They also highlight planned software offerings, including an Autonomy+ subscription and AI-enabled in-vehicle features, as potential high-margin, recurring revenue streams that could reshape the company’s economics. The recent stock rally occurs despite ongoing operating losses and broader electric vehicle demand challenges.

HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX

Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.

Or subscribe with

Read other top news stories

Marijuana Rescheduling Ordered by Trump

Marijuana Rescheduling Ordered by Trump

Marijuana rescheduling could let cannabis firms claim federal tax deductions and expand research, prompting traders to reprice margins and cannabis stocks.

FedEx Earnings Lift Outlook After Q2 Revenue Rise

FedEx Earnings Lift Outlook After Q2 Revenue Rise

FedEx earnings showed Q2 revenue of $23.5 billion and stronger margins, prompting a raised fiscal-2026 outlook that could shift near-term positioning.

Nike Earnings Test 'Win Now' Turnaround

Nike Earnings Test 'Win Now' Turnaround

Nike earnings will test CEO Elliott Hill's Win Now plan as Q2 revenue, China weakness and margin pressure shape near-term trader positioning and flows.

Darden Restaurants Earnings Lift Sales Outlook

Darden Restaurants Earnings Lift Sales Outlook

Darden Restaurants earnings showed Q2 same-restaurant gains at Olive Garden and LongHorn that lifted the FY2026 sales outlook and spurred repositioning.

Eli Lilly Orforglipron Maintains Weight Loss

Eli Lilly Orforglipron Maintains Weight Loss

Eli Lilly orforglipron met maintenance endpoints and Lilly filed for FDA review, which could speed approval and alter commercial positioning.

Birkenstock Earnings Beat as Tariff Concerns Rise

Birkenstock Earnings Beat as Tariff Concerns Rise

Birkenstock earnings topped guidance on Dec. 18, 2025, and the company warned tariffs and production limits will slow FY2026 growth and pressure shares.